$206 Million is the total value of Euclidean Capital LLC's 10 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | Sell | PMV PHARMACEUTICALS INC | $82,540,000 | -38.2% | 2,769,813 | -29.1% | 40.12% | -7.4% |
| ALEC | ALECTOR INC | $22,384,000 | +9.6% | 980,894 | 0.0% | 10.88% | +64.1% | |
| RAPT | Sell | RAPT THERAPEUTICS INC | $19,722,000 | -15.7% | 635,177 | -13.7% | 9.59% | +26.3% |
| New | TENAYA THERAPEUTICS INC | $18,909,000 | – | 915,705 | +100.0% | 9.19% | – | |
| FHTX | FOGHORN THERAPEUTICS INC | $17,569,000 | +30.5% | 1,261,261 | 0.0% | 8.54% | +95.5% | |
| NGM | Sell | NGM BIOPHARMACEUTICALS INC | $17,494,000 | -40.6% | 832,274 | -44.3% | 8.50% | -11.0% |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $16,251,000 | -7.8% | 777,193 | -22.0% | 7.90% | +38.0% |
| New | SURROZEN INC | $5,685,000 | – | 802,965 | +100.0% | 2.76% | – | |
| FFBC | FIRST FINL BANCORP OH | $4,063,000 | -1.0% | 173,576 | 0.0% | 1.98% | +48.4% | |
| PDD | Buy | PINDUODUO INCsponsored ads | $1,112,000 | -10.8% | 12,262 | +25.0% | 0.54% | +33.9% |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -25,866 | -100.0% | -0.40% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -31,131 | -100.0% | -1.30% | – |
| NRIX | Exit | NURIX THERAPEUTICS INC | $0 | – | -154,426 | -100.0% | -1.33% | – |
| SNOW | Exit | SNOWFLAKE INCcl a | $0 | – | -47,136 | -100.0% | -3.70% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -554,325 | -100.0% | -6.08% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -323,749 | -100.0% | -8.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.